Talis Biomedical Corp Stock Net Asset
Talis Biomedical Corp fundamentals help investors to digest information that contributes to Talis Biomedical's financial success or failures. It also enables traders to predict the movement of Talis Pink Sheet. The fundamental analysis module provides a way to measure Talis Biomedical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Talis Biomedical pink sheet.
Talis |
Talis Biomedical Corp Company Net Asset Analysis
Talis Biomedical's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Talis Biomedical Net Asset | 98.34 M |
Most of Talis Biomedical's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Talis Biomedical Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Talis Biomedical Corp has a Net Asset of 98.34 M. This is much higher than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Talis Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Talis Biomedical's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Talis Biomedical could also be used in its relative valuation, which is a method of valuing Talis Biomedical by comparing valuation metrics of similar companies.Talis Biomedical is currently under evaluation in net asset category among its peers.
Talis Fundamentals
Return On Equity | -0.7 | ||||
Return On Asset | -0.3 | ||||
Operating Margin | (113.60) % | ||||
Current Valuation | (38.24 M) | ||||
Shares Outstanding | 1.82 M | ||||
Shares Owned By Insiders | 8.30 % | ||||
Shares Owned By Institutions | 52.15 % | ||||
Number Of Shares Shorted | 17.96 K | ||||
Price To Book | 0.06 X | ||||
Price To Sales | 19.57 X | ||||
Revenue | 412 K | ||||
Gross Profit | (149.4 M) | ||||
EBITDA | (60.7 M) | ||||
Net Income | (62.01 M) | ||||
Cash And Equivalents | 165.37 M | ||||
Cash Per Share | 6.21 X | ||||
Total Debt | 19.67 M | ||||
Debt To Equity | 0.19 % | ||||
Current Ratio | 12.51 X | ||||
Book Value Per Share | 26.68 X | ||||
Cash Flow From Operations | (53.24 M) | ||||
Short Ratio | 0.59 X | ||||
Earnings Per Share | (28.02) X | ||||
Target Price | 5.0 | ||||
Number Of Employees | 99 | ||||
Beta | 1.62 | ||||
Market Capitalization | 7.98 M | ||||
Total Asset | 98.34 M | ||||
Retained Earnings | (539.96 M) | ||||
Working Capital | 68.91 M | ||||
Net Asset | 98.34 M |
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Consideration for investing in Talis Pink Sheet
If you are still planning to invest in Talis Biomedical Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talis Biomedical's history and understand the potential risks before investing.
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |